Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clotiazepam is a thienodiazepine derivative belonging to the benzodiazepine class, used primarily for the short-term management of anxiety disorders and insomnia. It possesses anxiolytic, sedative, hypnotic, anticonvulsant, amnesic, and skeletal muscle relaxant properties. Its mechanism of action involves binding as a full agonist to the benzodiazepine site on the Gamma aminobutyric acid type A receptor (GABA A receptor) complex in the central nervous system. This enhances GABAergic neurotransmission by increasing chloride ion influx through GABA A receptor channels, leading to neuronal hyperpolarization and reduced excitability. The drug is rapidly absorbed after oral administration and has a relatively short elimination half-life (approximately 4–18 hours), resulting in less accumulation with repeated dosing compared to longer acting benzodiazepines. It is metabolized hepatically via oxidation into hydroxy-clotiazepam and desmethyl-clotiazepam[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clotiazepam.